Effect of 1,25-dihydroxyvitamin D3, Treatment on Insulin Secretion and Muscle Strength in Pre-diabetic Persons

Inclusion Criteria: * Body mass index (BMI) of \>24kg/m2 * Fasting serum glucose \<126 mg/dL Exclusion Criteria: * BMI\</=24 kg/m2 * Fasting serum glucose \>/=126 mg/dL * Patient is taking Calcium or Vitamin D supplements and is unwilling to stop for 8 weeks * Serum Calcium \>10.2 mg/dL * Serum inorganic phosphorous \>4.5mg/dL * Pregnancy or breastfeeding * Diagnosis of Diabetes Mellitus * Diagnosis of Rheumatoid Arthritis * Diagnosis of Chronic Obstructive Pulmonary Disease (COPD) * Renal in sufficiency/failure ( serum creatinine \>1.5 mg/dL men, \> 1.3 mg/dL women) * Chronic active liver disease (bilirubin \>1.2 mg/dL, AST\>144IU/L, or ALT \>165 IU/L) * History of chronic hepatitis * Active coronary artery disease ( unstable angina, myocardial infarction, stroke and revascularization of coronary, peripheral or carotid artery within the last 3 months) * Oral warfarin group medications or history of blood clotting disorders * Platelet count \<100,000 per uL within the last 7 days * Alcohol consumption greater than 2 glasses/day or other substance abuse * Untreated or uncontrolled thyroid disorders (outside a TSH range of 0.5 to 10mIU/L) * Debilitating chronic disease (at the discretion of the investigators) * The presence of infections, highly communicable diseases ( AIDS, active tuberculosis, venereal disease, hepatitis) * Any malignancy